公司資料
Arcus Biosciences 股價、新聞與催化劑
- 股票代碼:
- RCUS
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
25.23 USD (-2.32%)
收盤價
最後更新: 2026年10月1日
3.08B USD
市值
股價為何變動
截至 2026年10月1日，RCUS 下跌 2.32%，收於 $25.23。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Clinical-Stage Oncology and Immunology Company
Arcus Biosciences develops differentiated medicines for cancer and immune-mediated diseases. Its research model combines internally discovered molecules, biomarker-driven clinical development, and collaborations that can broaden the number and scale of combination studies.
Casdatifan Kidney Cancer Franchise
Casdatifan is an oral HIF-2α inhibitor being developed as a potential backbone therapy for clear-cell renal cell carcinoma. Arcus is studying the molecule as monotherapy and in combinations with zimberelimab, cabozantinib, and other agents across first-line, second-line, and later-line settings.
Quemliclustat in Pancreatic Cancer
Quemliclustat is a small-molecule CD73 inhibitor designed to reduce immunosuppressive adenosine in the tumor microenvironment. The program has advanced into the Phase 3 PRISM-1 study in metastatic pancreatic cancer in combination with chemotherapy.
Checkpoint and Combination Capabilities
Zimberelimab, an anti-PD-1 antibody, supports Arcus-controlled immuno-oncology combinations and may reduce dependence on externally sourced checkpoint inhibitors. The company also uses partnerships, including its alliance with Gilead, to fund and execute broad late-stage development programs.
Emerging Immunology Pipeline
Arcus is extending its discovery platform beyond oncology through AB102, an MRGPRX2-targeting antibody for mast-cell-driven diseases, and an oral TNF inhibitor. These programs add allergic and inflammatory disorders to a pipeline historically centered on solid tumors.
未來催化劑
- Multiple ARC-20 casdatifan datasets in renal cell carcinoma during the second half of 2026, including first-line combinations, second-line casdatifan plus cabozantinib, and late-line monotherapy follow-up.
- Initiation of the Phase 3 PEAK-20 casdatifan study by year-end 2026.
- Completion of enrollment in the Phase 3 PEAK-1 casdatifan study by year-end 2026.
- Phase 3 PRISM-1 results for quemliclustat in metastatic pancreatic cancer in the first half of 2027.
- Initial clinical proof-of-concept data for AB102 in mast-cell-driven disease around mid-2027.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。